B. Castella

发表

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells

N. Mitro, D. Caruso, J. Kopecka, 2017, Nature Communications.

Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition

E. Gazzano, J. Kopecka, C. Riganti, 2013, Molecular Cancer.

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+

F. Malavasi, V. Pistoia, D. Marimpietri, 2018, Oncoimmunology.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer

M. Donadelli, E. Gazzano, J. Kopecka, 2018, Journal of Experimental & Clinical Cancer Research.

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

C. Riganti, M. Massaia, B. Castella, 2018, Front. Oncol..

Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside

M. Coscia, M. Massaia, B. Castella, 2011, Cellular and Molecular Life Sciences.

Unconventional properties of zoledronic acid

S. Mariani, M. Massaia, S. Peola, 2009 .

Direct and indirect antitumor activity of zoledronic acid

S. Mariani, F. Pantaleoni, M. Massaia, 2009 .

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells

C. Riganti, M. Massaia, B. Castella, 2018, Front. Immunol..

immunity on short-term incubation with zoledronic acid Enhanced ability of dendritic cells to stimulate innate and adaptive

M. Boccadoro, S. Mariani, F. Pantaleoni, 2013 .

Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells

M. Boccadoro, C. Riganti, A. Bosìa, 2011, The Journal of Immunology.

Talk between V Human Myeloma : An Advantageous Cross Immune Modulation by Zoledronic Acid in

M. Boccadoro, C. Riganti, A. Bosìa, 2011 .

Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.

M. Boccadoro, S. Mariani, B. Bruno, 2007, Blood.

Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia

M. Boccadoro, B. Bruno, D. Ferrero, 2020, British Journal of Haematology.

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells

M. Boccadoro, C. Riganti, M. Ladetto, 2015, Oncotarget.

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status

M. Boccadoro, S. Mariani, A. Palumbo, 2014, Haematologica.

Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

M. Boccadoro, S. Mariani, A. Palumbo, 2005, Leukemia.

Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma

M. Boccadoro, S. Mariani, A. Palumbo, 2005, Leukemia.

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

R. Foà, S. Chiaretti, M. Boccadoro, 2012, Blood.

Dysfunctional V 9 V 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells *

R. Foà, S. Chiaretti, M. Boccadoro, 2012 .

Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations

S. Strom, F. Malavasi, A. Horenstein, 2018, The Journal of Immunology.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

E. Gazzano, J. Kopecka, C. Riganti, 2020, Seminars in cell & developmental biology.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors

P. Jänne, M. Capelletti, G. Inghirami, 2015, Cancer Immunology Research.

Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status

A. Larocca, J. Kopecka, C. Riganti, 2022, Frontiers in Immunology.

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

C. Riganti, M. Massaia, B. Castella, 2018, Front. Immunol..

An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells

B. Rolando, E. Gazzano, J. Kopecka, 2015, PloS one.

Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells

J. Kopecka, C. Riganti, D. Ghigo, 2013, PloS one.

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

R. Foà, S. Chiaretti, P. Chiusolo, 2022, Haematologica.

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells

M. Boccadoro, C. Riganti, M. Ladetto, 2011, Leukemia.

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma

M. Boccadoro, C. Riganti, A. Palumbo, 2015, Oncoimmunology.

Molecular dynamics of targeting CD38 in multiple myeloma

P. Richardson, F. Malavasi, S. Oliviero, 2021, British journal of haematology.

CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab

R. Mina, F. Gay, B. Castella, 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

CD38 and Antibody Therapy: What Can Basic Science Add?

F. Malavasi, A. Horenstein, D. Incarnato, 2016 .

Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia

M. Boccadoro, D. Sblattero, S. Deaglio, 2016, Oncotarget.